Literature DB >> 9049966

Interferon-inducible protein-10 and the pathogenesis of cutaneous T-cell lymphomas.

A H Sarris1, D Daliani, R Ulmer, M Crow, H E Broxmeyer, W Pugh, M Reiss, F Cabanillas, A B Deisseroth, M Duvic.   

Abstract

Human interferon-g inducible protein-10 (IP-10), a small basic protein secreted by interferon (INF)-g stimulated keratinocytes, is chemotactic for normal CD4-positive lymphocytes and inhibits early normal and leukemic hemopoietic progenitor proliferation. Cutaneous T-cell lymphoma (CTCL) is an indolent CD4-positive lymphoma characterized by multiple skin relapses before visceral dissemination. We investigated the role of IP-10 in the biology of CTCL by using immunocytochemistry to define IP-10 expression in normal and CTCL skin biopsies. Using purified recombinant (r) IP-10, we generated a rabbit antiserum that recognized and neutralized rIP-10 but did not cross-react with any keratinocyte proteins or any other chemokine. Immunoperoxidase staining of normal epidermis demonstrated that IP-10 was expressed by basal but not by differentiated keratinocytes. The epidermis overlying CTCL lesions was often hyperplastic, IP-10 immunostaining was enhanced compared to normal skin, and extended to the suprabasal keratinocytes in 25 of 26 patients for a frequency of 96%; and 95% confidence interval (CI) of 80% to 100%. However, IP-10 was detectable in the dermal or epidermal lymphoid infiltrates in only three of these 26 patients (12%; 95% Cl, 2% to 39%). Skin clinically free of CTCL demonstrated normal IP-10 immunostaining. In one patient who had matching biopsies performed before and after treatment, IP-10 was initially overexpressed before treatment but was normally expressed when he achieved remission. These results suggest that IP-10 may play a role in the epidermotropism of CTCL. More work is required to determine whether IP-10 stimulates or inhibits CTCL proliferation. A better understanding of the growth controls operating in CTCL may be used to develop curative therapies for this disorder.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9049966     DOI: 10.3109/10428199609045718

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

Review 1.  Cutaneous T-cell lymphoma in a cardiac transplant recipient.

Authors:  D M McMullan; B Radovaneević; C M Jackow; O H Frazier; M Duvic
Journal:  Tex Heart Inst J       Date:  2001

2.  Therapeutic Toll-like receptor agonists directly influence mouse and human T cell lymphoma cell viability and cytokine secretion.

Authors:  Angela Landrigan; Gloria Yiu; Kanika Agarwal; Paul J Utz
Journal:  Leuk Lymphoma       Date:  2011-09-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.